Evidence map›Paper›PMID 31035393›Full record

ReviewInternational journal of molecular sciences2019

Macrocyclic Compounds for Drug and Gene Delivery in Immune-Modulating Therapy.

Hongzhen Bai, Jianwei Wang, Zhongbao Li, Guping Tang

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Mitigating atherosclerosis: Integrating vaccines with gene targets.American heart journal plus : cardiology research and practice · 2025
    Review
  3. Review
  4. Article
  5. Host-Guest Complexes.International journal of molecular sciences · 2022
    Article
  6. Article
  7. The Physical Chemistry and Chemical Physics (PCCP) Section of theInternational journal of molecular sciences · 2021
    Article
  8. Suppression of Malachite Green-Induced Toxicity to Human Liver Cells Utilizing Host-Guest Chemistry of Cucurbit[7]uril.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2021
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hongzhen BaiDepartment of Chemistry, Zhejiang University, Hangzhou 310028, China. hongzhen_bai@zju.edu.cn.
Jianwei WangDepartment of Chemistry, Zhejiang University, Hangzhou 310028, China. wjw126hz@zju.edu.cn.
Zhongbao LiDepartment of Chemistry, Zhejiang University, Hangzhou 310028, China. 21637025@zju.edu.cn.
Guping TangDepartment of Chemistry, Zhejiang University, Hangzhou 310028, China. tangguping@zju.edu.cn.
Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For decades, macrocyclic compounds have been widely applied in various fields owing to essential physicochemical properties such as their rigid cyclic structures, geometric dimensions (diameter and height), hydrophobic cavity, and hydrophilic interface. This review is an attempt to summarize various research accomplishments involving macrocyclic compounds for drug and gene delivery in immune-modulating therapies: the structures and benefits of main host molecules, their mechanisms regulating the immune system from cell uptake to activation of dendritic cells and T helper lymphocytes, as well as their potential immunotherapy for different diseases. Macrocyclic compounds including cucurbiturils (CBs), calixarenes, pillararenes, cyclodextrins (CyDs), macrocyclic peptides and metallo-supramolecular compounds, have their own unique physicochemical properties and functional derivatizations that enable to improve the biocompatibility, responsiveness to stimuli, and effectiveness of immune-modulating therapy. Based on abundant clarifications of the biological immunity mechanisms, representative constructions of macrocyclic compounds for immune therapies have been conducted for the investigation of treatment of different diseases including cancer, atherosclerosis, Niemann-Pick type C1 disease (NPC1), diabetes, and inflammations. Although there are critical challenges that remain to be conquered, we believe the future of macrocyclic compounds in the immune-modulating therapy must be bright.

Indexed as

AnimalsDrug Delivery SystemsGene Transfer TechniquesHumansImmunotherapyMacrocyclic CompoundsMacrocyclic Compoundsdrug and gene deliveryimmune-modulating therapyimmunity mechanismsmacrocycliccompoundsphysicochemical properties

Identifiers

PMID31035393
PMCPMC6539895
OpenAlexW2941323984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.